5 Best Healthcare Stocks For Recession

4. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Number of Hedge Fund Holders: 52

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a biotech company. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) gained about 100% in value in 2022. The future outlook of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is also strong, which makes it one of the best healthcare stocks for recession. Earlier this month Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced that its net product revenue in Q4 was expected to come in at about $235.5 million, which would be about 32% more than the revenue posted in the comparable period last year. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) said this revenue growth was driven by its three RNA-based PMO therapies. In November, FDA accepted Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s marketing application for gene therapy candidate SRP-9001. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) makes this treatment with Roche.

Hedge fund sentiment for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) spiked in the third quarter of 2022. Of the 920 funds tracked by Insider Monkey, 52 funds reported having stakes in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) at the end of the third quarter, compared to 41 funds in the previous quarter.